Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising DTx Pharma on the transaction. A preclinical-stage biotechnology company, DTx Pharma announced that it has been acquired by Novartis. In addition...
You must be a Standard 1 Year member to access this content.
Wilson, Sonsini is acting as legal counsel to Amphastar. Kirkland & Ellis and Covington & Burling are acting as legal counsel to Lilly. In an effort...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aadi Bioscience on the deal while Goodwin Procter LLP represented Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals and Aadi Bioscience announced their...
You must be a Standard 1 Year member to access this content.
